nach oben

International Journal of Colorectal Disease

Erschienen in:

09.05.2020 | Review

Clinical remission of ulcerative colitis after different modes of faecal microbiota transplantation: a meta-analysis

verfasst von: Li-li Tang, Wen-zhe Feng, Jia-jun Cheng, Yan-ni Gong

Erschienen in: International Journal of Colorectal Disease | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Ulcerative colitis (UC) is a chronic, recurrent and destructive disease of the gastrointestinal tract. Faecal microbiota transplantation (FMT) is a therapeutic measure in which faecal microbiota from healthy people is transplanted into patients.

Aim

To systematically evaluate the safety and effectiveness of treating UC with different modes of FMT.

Methods

Seven databases were searched by two independent researchers and studies related to randomized controlled trials were included in the analysis.

Results

Seven studies on UC involving 431 patients were included in the analysis. The results showed that FMT had better efficacy than placebo (OR = 2.29, 95% CI 1.48–3.53, P = 0.0002). Subgroup analyses of influencing factors showed that frozen faeces from multiple donors delivered via the lower gastrointestinal tract had a better curative effect than placebo (OR = 2.76, 95% CI 1.59–4.79, P = 0.0003; OR = 2.93, 95% CI 1.67–5.71, P = 0.0002; and OR = 2.70, 95% CI 1.67–4.37, P < 0.0001); the difference in efficacy between mixed faeces from a single donor transplanted through the upper gastrointestinal tract and placebo was not significant(P = 0.05, P = 0.09 and P = 0.98). The analysis of side effects showed no significant difference between FMT and placebo (P = 0.43).

Conclusions

It may be safe and effective to transplant frozen faeces from multiple donors through the lower gastrointestinal tract to treat UC.

Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577–594PubMedCrossRef

Ahuja V, Tandon RK (2010) Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis 11:134–147PubMedCrossRef

Dahlhamer JM, Zammitti EP, Ward BW et al (2016) Prevalence of inflammatory bowel disease among adults aged ≥ 18 years—United States, 2015. Morb Mortal Wkly Rep 65:1166–1169CrossRef

Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46–54PubMedCrossRef

Weintraub Y, Mimouni FB, Cohen S (2014) Temporal trends in inflammatory bowel disease publications over a 19-years period. World J Gastroenterol 20:16745–16749PubMedPubMedCentralCrossRef

Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl J Med 361:2066–2078PubMedPubMedCentralCrossRef

Vindigni SM, Zisman TL, Suskind DL, Damman CJ (2016) The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Ther Adv Gastroenterol 9:606–625CrossRef

Assa A, Butcher J, Li J, Elkadri A, Sherman PM, Muise AM, Stintzi A, Mack D (2016) Mucosa-associated ileal microbiota in new-onset pediatric Crohn’s disease. Inflamm Bowel Dis 22:1533–1539PubMedCrossRef

Bejaoui M, Sokol H, Marteau P (2015) Targeting the microbiome in inflammatory bowel disease: critical evaluation of current concepts and moving to new horizons. Dig Dis 33:105–112PubMedCrossRef

10.

Kostic AD, Xavier RJ, Gevers D (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146:1489–1499PubMedCrossRef

11.

Smits LP, Bouter KE, de Vos WM et al (2013) Therapeutic potential of fecal microbiota transplantation. Gastroenterology 145:946–953PubMedCrossRef

12.

Cao Y, Shen J, Ran ZH (2014) Association between Faecalibacterium prausnitzii reduction and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Gastroenterol Res Pract:1–7

13.

Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G (2015) Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis 15:191PubMedPubMedCentralCrossRef

14.

Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL (2014) Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312:1772–1778PubMedCrossRef

15.

Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G (2015) Update on fecal microbiota transplantation 2015:indications, methodologies, mechanisms, and outlook. Gastroenterology 149:223–237PubMedCrossRef

16.

Moore T, Rodriguez A, Bakken JS (2014) Fecal microbiota transplantation: a practical update for the infectious disease specialist. Clin Infect Dis 58:541–545PubMedCrossRef

17.

Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org

18.

Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef

19.

Sood A, Mahajan R, Singh A, Midha V, Mehta V, Narang V, Singh T, Singh Pannu A (2019) Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohn's Colitis 13:1311–1317CrossRef

20.

Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, Rosewarne CP, Bickley C, Peters C, Schoeman MN, Conlon MA, Roberts-Thomson IC, Andrews JM (2019) Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321:156–164PubMedPubMedCentralCrossRef

21.

Crothers J, Kassam Z, Smith M et al (2018) A double-blind, randomized, placebo-control pilot trial of fecal microbiota transplantation capsules from rationally selected donors in active ulcerative colitis. Gastroenterology 154:S-1050–S-1051CrossRef

22.

Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149:102–109PubMedCrossRef

23.

Rossen NG, Fuentes S, Van Der Spek MJ, et al (2015) Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. 149:110–118

24.

Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389:1218–1228PubMedCrossRef

25.

Mahajan R, Midha V, Mehta V et al (2018) Faecal microbiota transplantation for maintenance of clinical remission in patients with active ulcerative colitis: a randomised control trial. Gut 67:A300

26.

Cosnes J, Gower-Rousseau C, Seksik P et al (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140:1785–1794PubMedCrossRef

27.

Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong A, Weersma RK, Wilson DC, International Inflammatory Bowel Disease Genetics Consortium, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern D, Barrett JC, Lees CW (2016) Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet 387:156–167PubMedPubMedCentralCrossRef

28.

Khajah MA (2017) The potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease. Scand J Gastroenterol 52:1172–1184PubMedCrossRef

29.

Andoh A, Sakata S, Koizumi Y, Mitsuyama K, Fujiyama Y, Benno Y (2007) Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis 13:955–962PubMedCrossRef

30.

Zhang L, Dong D, Jiang C, Li Z, Wang X, Peng Y (2015) Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Anaerobe 34:1–7PubMedCrossRef

31.

Borody TJ, Paramsothy S, Agrawal G (2013) Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 15:013–0337CrossRef

32.

Packey CD, Sartor RB (2009) Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 22:292–301PubMedPubMedCentralCrossRef

33.

Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J (2006) Reduced diversity of faecal microbiota in Crohn’s disease revealed by a meta-genomic approach. Gut 55:205–211PubMedPubMedCentralCrossRef

34.

Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736PubMedPubMedCentralCrossRef

35.

Frank DN, St Amand AL, Feldman RA et al (2007) Molecular-phylogen-etic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785PubMedPubMedCentralCrossRef

36.

Rehman A, Lepage P, Nolte A, Hellmig S, Schreiber S, Ott SJ (2010) Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. J Med Microbiol 59:1114–1122PubMedCrossRef

37.

Lepage P, Hasler R, Spehlmann ME et al (2011) Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141:227–236PubMedCrossRef

38.

Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N (2003) Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 52:79–83PubMedPubMedCentralCrossRef

39.

Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, DeVinney R, Lynch T, Allen-Vercoe E (2011) Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 17:1971–1978PubMedCrossRef

40.

Nemoto H, Kataoka K, Ishikawa H, Ikata K, Arimochi H, Iwasaki T, Ohnishi Y, Kuwahara T, Yasutomo K (2012) Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig Dis Sci 57:2955–2964PubMedCrossRef

41.

Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79PubMedPubMedCentralCrossRef

42.

Damman CJ, Miller SI, Surawicz CM, Zisman TL (2012) The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 107:1452–1459PubMedCrossRef

43.

Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G (2014) Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine 93:e97PubMedPubMedCentralCrossRef

44.

Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7:1202–1209PubMedCrossRef

45.

Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodinoʼ S, DʼAmico T, Sebkova L, Saccaʼ N, di Giulio E, Luzza F, Imeneo M, Larussa T, di Rosa S, Annese V, Danese S, Gasbarrini A (2010) Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment:a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105:2218–2227PubMedPubMedCentralCrossRef

46.

Colman RJ, Rubin DT (2014) Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohn's Colitis 8:1569–1581CrossRef

47.

Aas J, Gessert CE, Bakken JS (2003) Recurrent clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36:580–585PubMedCrossRef

48.

Levy AN, Allegretti JR (2019) Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease. Ther Adv Gastroenterol 12:1–10CrossRef

49.

Cammarota G, Masucci L, Ianiro G, Bibbo S, Dinoi G, Costamagna G et al (2015) Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 41:835–843PubMedCrossRef

50.

Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, Ropeleski MJ, Jayaratne P, Higgins D, Li Y, Rau NV, Kim PT (2016) Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 315:142–149PubMedCrossRef

51.

van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–415PubMedCrossRef

52.

Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, Hohmann EL (2014) Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 58:1515–1522PubMedPubMedCentralCrossRef

53.

Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L (2014) Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109:1065–1071PubMedPubMedCentralCrossRef

54.

Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, Sadowsky MJ (2016) Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 14:1433–1438PubMedPubMedCentralCrossRef

55.

Cammarota G, Ianiro G, Tilg H, Rajili-Stojanovi M, Kump P, Satokari R et al (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66:569–580PubMedCrossRef

56.

Alang N, Kelly CR (2015) Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2:ofv004PubMedPubMedCentralCrossRef

Titel: Clinical remission of ulcerative colitis after different modes of faecal microbiota transplantation: a meta-analysis
verfasst von: Li-li Tang
Wen-zhe Feng
Jia-jun Cheng
Yan-ni Gong
Publikationsdatum: 09.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: International Journal of Colorectal Disease / Ausgabe 6/2020
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-020-03599-7

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Patterns of tined lead migration in sacral nerve modulation

Sinusectomy and primary closure versus excision and primary closure in pilonidal sinus disease: a retrospective cohort study

Failure of enhanced recovery after surgery in laparoscopic colorectal surgery: a systematic review

Long-term outcomes of single-incision laparoscopic technique in Soave procedure compared with heart-shaped anastomosis for Hirschsprung disease

Scoring systems as outcomes assessment of the treatments for haemorrhoidal disease: a systematic review of the literature

Social determinants of colorectal cancer risk, stage, and survival: a systematic review

Update Chirurgie